GlassScriptPhysician profile
Amar Arunachalam
NPI 1750842118
$2,332.08
in general payments reported to CMS, 2019-2025
23 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $201 · 2024: $154 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.08 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $277.88 | 2025 | Minimed 780g |
| Corcept Therapeutics | $261.72 | 2024-2025 | Korlym |
| Lilly USA, LLC | $236.24 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.47 | 2025 | Jardiance |
| Insulet Corporation | $151.03 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $132.98 | 2025 | |
| Xeris Pharmaceuticals, INC. | $118.90 | 2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $113.33 | 2023-2025 | |
| Mannkind Corporation | $86.54 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $68.62 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $64.09 | 2025 | Yorvipath |
| Amgen INC. | $59.20 | 2025 | Repatha |
| Abbvie INC. | $58.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $39.68 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $33.15 | 2025 | Nexletol |
| Alexion Pharmaceuticals, INC. | $30.81 | 2024 | |
| Glaxosmithkline, LLC. | $22.99 | 2025 | Shingrix, Arexvy |
| Soleno Therapeutics, INC. | $22.81 | 2025 | Vykat Xr |
| Dexcom, INC. | $19.21 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $17.85 | 2024 | Opdivo |
| Acella Pharmaceuticals, LLC | $16.19 | 2025 | NP Thyroid 60 |
| Amphastar Pharmaceuticals, INC. | $15.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Arunachalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.